Legend Biotech (LEGN) Financial Analysis & Valuation | Quarter Chart
Legend Biotech (LEGN)
LEGNPrice: $29.39
Fair Value: 🔒
🔒score
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeri... more
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, en... more
Description
Shares
| Market Cap | $5.44B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Ying Huang |
| IPO Date | 2020-06-05 | CAGR | 0.6% |
| Employees | 2,900 | Website | www.legendbiotech.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
LEGN chart loading...
Fundamentals
Technicals
| Enterprise Value | $3.05B | P/E Ratio | -43.22 |
| Forward P/E | 21.3 | PEG Ratio | — |
| P/S Ratio | 4.56 | P/B Ratio | 5.37 |
| P/CF Ratio | -29.64 | P/FCF Ratio | -22 |
| EPS | $-0.68 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 56.37% | Gross Margin | 0.55% |
| Operating Margin | -0.12% | Profit Margin | -0.22% |
| ROE | -0.25% | ROA | -0.16% |
| ROCE | -0.12% | Current Ratio | 2.13 |
| Quick Ratio | 2.05 | Cash Ratio | 1.27 |
| Debt/Equity | 0.4 | Interest Coverage | -6.21 |
| Altman Z Score | 4.07 | Piotroski Score | 3 |